ProfileGDS5678 / 1418590_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 67% 67% 72% 65% 68% 68% 66% 68% 66% 65% 67% 67% 65% 67% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.0505767
GSM967853U87-EV human glioblastoma xenograft - Control 24.0908867
GSM967854U87-EV human glioblastoma xenograft - Control 34.6480272
GSM967855U87-EV human glioblastoma xenograft - Control 43.9412865
GSM967856U87-EV human glioblastoma xenograft - Control 54.1975168
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1985168
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0630966
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2100668
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0250566
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8777265
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0363967
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0401167
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9468865
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.0440167